NRIX Similar Chart Price Prediction
The price of NRIX is predicted to go up 35.92%, based on the high correlation periods with AHG. The similarity of these two price pattern on the periods is 98.68%.
NRIX
AHG
Up: 35.92%Similarity: 98.68%
NRIX Revenue Forecast
NRIX EPS Forecast
NRIX FAQs
What is NRIX revenue forecast for next quarter？
What is NRIX eps forecast for next quarter？
NRIX Analyst's Forecast
Jeet Mukherjee
BTIG
Strong Buy
2024-12-10
Price Target
$35
Upside
+58.66%
BTIG initiated coverage of Nurix Therapeutics with a Buy rating and $35 price target. Nurix is a protein degrader company whose lead BTK - Bruton's tyrosine kinase - degrader program, NX-5948, has the potential to differentiate in the large $8B market opportunity in BTK driven cancers, the analyst tells investors in a research note. Despite the strong 2024 performance for the stock, the firm still likes the investment story heading into 2024-end and 2025 given additional response rate and durability data expected for NX-5948 in CLL at ASH, initial Phase 1 data for CBL-B inhibitor NX-1607 in Relapsed/Refractory solid tumors by YE24, and updated Phase 1 data for BTK/IKZF degrader NX-2127 in 2025, BTIG adds.
David Dai
UBS
Strong Buy
2024-10-24
Price Target
$35
Upside
+38.78%
Roger Song
Jefferies
Strong Buy
2024-10-11
Price Target
$41
Upside
+73.51%
